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Steady- state enzyme kinetics
Steady- state enzyme kinetics is a cornerstone technique of biochemistry and related sciences since it 
allows the characterization and quantification of enzyme behaviour. Enzyme kinetics is widely used 
to investigate the physiological role of enzymes, determine the effects of mutations and characterize 
enzyme inhibitors. Well- known examples of enzyme inhibitors used to treat diseases include anti- 
infectives (e.g., penicillin, clavulanic acid and HIV protease inhibitors); anti- inflammatories (e.g., aspirin 
and ibuprofen); cholesterol- lowering statins; tyrosine kinase inhibitors used to treat cancer; and 
Viagra. Commonly, new disease treatments are discovered by using enzyme kinetics to identify the 
few active compounds residing within a large compound collection (‘high- throughput screening’).
The subject of enzyme kinetics is typically introduced to first- year undergraduates with a mathematical 
description of behaviour. This Beginners Guide will give a brief overview of experimental enzyme 
kinetics and the characterization of enzyme inhibitors. Colorimetric assays using a microtitre plate will 
be considered, although most principles also apply to other assays.
Matthew D. Lloyd 
(University of Bath, UK)
Beginner’s Guide
Preliminary considerations
Steady- state kinetics measures rates at the beginning 
of the reaction time course (‘initial rates’) because 
this is when inhibitor effects are most easily seen, and 
complications are minimized. If possible, a continuous 
assay should be used with a coloured reaction product, 
as this allows the most accurate rate measurements. The 
reaction rate in change in absorbance per minute (ΔA 
min–1) can be converted into, e.g., nmol min–1 using 
the Beer–Lambert law (equation 1). If there is a choice 
of assays, the one where the product has the longest 
wavelength (as this will minimize background noise) 
and the product which is the most intensely coloured 
(has the largest extinction coefficient ε) should be used. 
Using the longest reporter wavelength also reduces assay 
interference by the inhibitor:
 A = εcl (1)
Product concentration (c in, e.g., molar, M) can be calcu-
lated from the absorbance at a particular wavelength (A) 
if the extinction coefficient (ε in, e.g., M–1 cm–1) and 
pathlength (l in cm) are known.
Special mention should be made of assays which 
follow 4- nitrophenol release from a substrate at 405 nm. 
4- Nitrophenoxide (deprotonated form) is very yellow (ε405 
= 18.1 mM–1 cm–1) whilst 4- nitrophenol (protonated form) 
is almost colourless (ε405 = 0.2 mM
–1 cm–1). The pKa of 
4- nitrophenol is 7.14, so at pH 7.5 only ~70% of product 
exists as 4- nitrophenoxide. A stopped assay where the 
reaction is quenched with, e.g., 0.1 M NaOH aq. at several 
time points is needed to ensure full colour development 
and the correct measurement of rates.
An amount of enzyme which gives a signal that can 
be easily distinguished from background noise needs to 
be used. Detergent is often included in assays to prevent 
inhibitor aggregation (which is a significant source of 
‘false- positive’ results in inhibitor studies). If more than 
one assay is available, then Z′ (equation 2) can be used 
to decide which assay performs the best. A Z′ value >0.5 
and ideally >0.7 is required. Once assay conditions have 
been finalized, the Km value for the substrate should be 
determined. Substrate concentrations at or close to the 












signal from positive control−signal from negative control 
 (2)
Equation 2 calculates the Z′ value, which can range 
between 0 and 1 (with 1 being a ‘perfect’ assay). SD is the 
standard deviation.
A final consideration is how to measure rates. 
Absorbance is measured over the required time course 
using a spectrophotometer or a plate reader, the latter 
allowing the reading of several samples at the same 
time. The simplest method of determining rates (i.e., 
ΔA min–1) is to plot absorbance vs time at low substrate 
conversions (‘initial rates’). This method is convenient 
but considerably under- estimates rates. An alternative is 
to fit absorbance readings over time to an integrated rate 
equation which gives better estimates and corrects for 
substrate depletion. An online program exists to derive 
rates from experimental data (see Olp et al., 2020) which 
also allows them to be corrected for the time between 
starting the reaction and the first measurement.
Dose–response curves and measurement 
of IC50 values
The first step in determining inhibitor activity is often to 
determine a dose–response curve. Enzyme is incubated 
with varying concentrations of inhibitor, e.g., for 10 







niversity of Bath user on 07 June 2021
41 June 2021 © The Authors. Published by Portland Press Limited under the Creative Commons Attribution License 4.0 (CC BY- NC- ND)
Beginner’s Guide
second but binding of inhibitor can be much slower than 
this. Many inhibitors have limited solubility in buffer 
and readily precipitate, and so concentrated inhibitor 
stocks should be prepared in DMSO and mixed with a 
larger volume of enzyme stock. At the end of the pre- 
incubation period, the sample is split into repeats, 
substrate solution added and rates measured.
A typical upper inhibitor concentration in the assay 
is 100 µM, although this may need to be increased for 
weakly binding inhibitors such as those identified from 
fragment screens. A 1 in 3 dilution series is used, which 
for 11 concentrations spans a range of 100 µM to 1.69 
nM. Two inhibitors can be measured in duplicate in 
each run, with the 12th positions occupied by positive 
and negative controls. A substrate concentration equal 
to the Km value is often used as this enables the effects of 
different inhibitors to be most easily observed (Figure 1).
The IC50 value is determined by plotting the reaction 
rate against Log10 molar drug concentrations, followed 
by fitting of the curve (Figure  2). For a well- behaving 
inhibitor, the enzymatic rates at the highest and lowest 
concentrations should be close to the negative and 
positive controls, respectively, and the slope in the 
middle part of the curve should be ~–1. Failure to 
behave in this way needs to be thoroughly investigated, 
as it means that there are problems with the inhibitor 
which may render it unusable (see Copeland for 
further details). Three independent determinations of 
IC50 values for each inhibitor are usually made. Log10 
molar inhibitor concentrations are generally used in 
dose- response curves, which means that results should 
be quoted as –log10 IC50 (usually denoted as pIC50) ± 
standard error of the mean. An important point is that 
the determined pIC50 value will depend on the substrate 
concentrationused in the assay (Figure 1).
The possibility of tight- binding inhibition should be 
considered with potent inhibitors (those with low IC50 
values). This occurs when the ratio of available drug to 
active enzyme is less than ~20:1 and often manifests itself 
by unusual dose–response curves. A detailed discussion 
is beyond the scope of this article and readers should 
consult the textbook by Copeland for further details.
Summary Box
• Behaviour of Michaelis- Menten enzymes is 
described by the kinetic parameters Vmax (the 
maximum rate of reaction under the specified 
conditions) and Km (substrate concentration at which 
the observed rate is half that of Vmax).
• Potency of inhibition can be determined using 
dose–response curves to measure the IC50 (the 
concentration of inhibitor which reduces enzyme 
activity to half that in its absence).
• Rapid dilution experiments can be used to assess 
inhibition reversibility.
• Reversible enzyme inhibitors can be competitive 
(Km increases), non- competitive (Vmax decreases), 
mixed competitive (Km increases, Vmax decreases) 
or uncompetitive (Km and Vmax are decreased to the 
same extent). Inhibitor potency is quantified using 
Ki (the concentration of inhibitor changing the 
observed Km and/or Vmax by twofold).
• Saturating irreversible inhibitors can be 
characterized using kinactivation (the maximum rate of 
inactivation) and KI (inhibitor concentration where 
inactivation is half its maximum rate).
Figure 1. Predicted IC50 values for various inhibitor types 
at various substrate concentrations, assuming Ki = 50 nM. 
The predicted IC50 value for mixed inhibitors depends 
on the proportion of competitive and non- competitive 
components of inhibition.
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Determining if the inhibitor is reversible
Proper characterization of an inhibitor requires a 
determination of whether it binds reversibly to the 
enzyme or not. A convenient method to determine 
this uses a rapid dilution experiment (Figure 3). In this 
experiment enzyme is incubated with inhibitor at 10× 
IC50 value, which should reduce reaction rates to ~10% 
of that in the positive control. In a second experiment, 
concentrated enzyme (e.g., 100× assay concentration) 
is incubated with inhibitor at 10× IC50. Immediately 
before assaying, the enzyme/inhibitor mixture is diluted 
such that enzyme is at the same concentration as in the 
positive control; this also dilutes the inhibitor (by 100× in 
this example, to 0.1× IC50 value). For a rapidly reversible 
inhibitor this results in restoration of activity to ~90% 
of that in the no- inhibitor positive control (Figure 3a). 
In contrast, little difference in rates is observed between 
the first and second experiments for an irreversible 
inhibitor (Figure  3b). Irreversible inhibition can arise 
when inhibitor binds covalently to the enzyme or when 
inhibitor binds to the enzyme non- covalently but the 
inhibitor is released slowly.
Determination of Ki values
Ki values are related to the thermodynamic strength of 
reversible inhibitor binding and are used to compare 
potencies between different reversible inhibitors. The 
most common method to determine Ki values is to 
measure enzymatic activity in the presence of variable 
substrate concentrations at several fixed inhibitor 
concentrations. A wide range of substrate concentrations 
should be used, e.g., 8 equally spaced concentrations 
between 0.1× and 10× Km, which gives rates between 
9% and 91% of Vmax. Inhibitor concentrations to be used 
in this experiment ([I]) can be conveniently calculated 
using equation 3. Inhibitor concentrations should be 
chosen to give rates of 75%, 50% and 25% (vi) of the 
uninhibited reaction (v0) (so v0/vi will be 1.33, 2 and 4, 
respectively):
 [I]= IC50 [(v0/vi) -1]
1/h (3)
Equation 3 is used for determining inhibitor concentra-
tions for steady- state kinetic analysis. The IC50 value is 
that determined when the substrate concentration in the 
assay is equal to its Km value, and h is the slope from the 
dose–response curve (the ‘Hill coefficient’).
The obtained data should be fitted to all types of 
inhibition (competitive, non- competitive, mixed and 
uncompetitive) for both dead- end (full) and partial 
inhibition modes (dead- end inhibition means that 
no enzyme activity remains at saturating inhibitor 
concentrations, whilst significant activity is present 
for a partial inhibitor under the same conditions). 
Competitive inhibitors will increase Km with no change 
in Vmax; non- competitive inhibitors decrease Vmax without 
changing Km; mixed competitive (a.k.a. mixed) inhibitors 
will have both effects; and uncompetitive inhibitors will 
decrease both Km and Vmax to the same extent. More than 
one viable solution will usually fit the data, and so the 
problem becomes how to tell which is the correct answer. 
This is done by inspection of various plots (Figure 4) and 
the use of statistical calculations.
Several plots can be used to analyse the data, 
including the Direct Linear plot (Figure  4a), the Direct 
(‘Michaelis–Menten’) plot (Figure  4b) and various linear 
transformations of the Michaelis–Menten equation 
(e.g., Figure  4c and d). Each plot has advantages and 
disadvantages and so all of them should be used in 
this analysis. In addition, a residuals plot showing the 
difference between calculated and observed rates vs 
Figure 3. A rapid dilution experiment with (a) a rapidly reversible inhibitor and (b) an irreversible inhibitor showing the 
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substrate and inhibitor concentrations (Figure  4e and f) 
should be produced, as this allows systematic deviations 
from predicted behaviour to be readily identified. The 
following steps usually result in the identification of the 
correct type of inhibition:
1. Examine the Direct Linear plot (Figure 4a) and ob-
serve the general trends for Km and Vmax values with 
increasing inhibitor concentrations.
2. Look at the statistical ranking of the different types 
of inhibition and check which are consistent with the 
trends observed in (1).
3. Look at the calculated kinetic parameters for the 
most likely solutions. Reject those where Km and Ki 
values are much larger or smaller than experimental 
substrate or inhibitor concentrations, or where Vmax 
is much larger or smaller than the observed rates. 
Figure 4. An illustration of kinetic plots for a mixed competitive inhibitor. Note that substrate and inhibitor concentrations 
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Reject any solutions with very large errors in any of 
the kinetic parameters.
4. Examine the Direct plot (Figure 4b), Eadie–Hofstee 
plot (Figure 4d) and residuals plots (Figure 4e and 
f) for the remaining solutions and look for system-
atic deviations. Examine the Lineweaver–Burk plot 
(Figure  4c) for points near the Y- axis departing 
from a straight line (substrate inhibition). The pres-
ence of significant deviations suggests the solution 
is not correct or more complex behaviour is being 
observed.
5. Apply Occam’s razor (which says that the simpler 
solution is usually correct). Partial inhibition (mixed 
inhibition in this case) usually gives a statistically 
‘better’ fit to the data, but this solution should be 
rejected if it makes little difference to Km, Vmax or Ki 
values and/or their associated errors.
6. The commonly observed types of inhibition are 
competitive and mixed competitive. Uncompetitive 
inhibition is rare but is occasionally observed. Non- 
competitive inhibition generally arises with multi- 
substrate enzymes, and the inhibitor will usually 
only behave in this way with one of the substrates. 
If non- competitive inhibition is observed, consider 
whether the inhibitor could be irreversible (see next 
section) or has aggregated (adding 0.1% detergent to 
the assay should diminish or abolish inhibition).
Irreversible inhibitors
The fundamental characteristic of irreversible inhibitors 
is that inhibition increases upon increasing the length of 
time that the enzyme is exposed to inhibitor. There are 
fundamentally two different types of irreversible inhibitor, 
those where inactivation rates saturate at higher inhibitor 
concentrations and those which do not. The former 
behaviour (Figure  5) usually indicates inhibitor binding 
to a defined pocket in the enzyme (often the active site), 
whilst the latter usually indicates binding to several non- 
specific sites. The latter behaviour is typically observed 
with non- specific protein modification reagents.
When characterizing an irreversible inhibition, 
concentrated enzyme is pre- incubated with several 
different concentrations of inhibitor and activity 
determined after different pre- incubation times. For most 
irreversible inhibitors, enzymatic activity decays with 
first- order kinetics at each fixed concentration. Plotting 
the natural logarithm (ln) of activity at the pre- incubation 
time point/activity at pre- incubation time = 0 vs time for 
each inhibitor concentration yields a series of straight lines 
(Figure 5a), with the slope corresponding to the first- order 
rate constant. Saturating inhibitors will show behaviour 
such as that displayed in Figure  5b when inactivation 
rates are plotted against inhibitor concentration. This 
allows determination of kinactivation (the maximum rate of 
inactivation) and KI (the inhibitor concentration at which 
the rate of inactivation is half its maximum value; not to 
be confused with Ki the reversible inhibitor constant). 
The effectiveness of different irreversible inhibitors can be 
compared using kinactivation/KI values.
Conclusions
Enzyme inhibitors are the single largest class of small- 
molecule drugs used in modern human and veterinary 
medicine and are highly successful. The development of 
new enzyme inhibitors for the treatment of many different 
diseases is being actively pursued. Enzyme kinetics will 
remain a key technique for the foreseeable future, for 
characterization of inhibitor properties, the optimization 
of drug potency and inhibitor identification by high- 
throughput screening and related techniques.■
Figure 5. Behaviour of a saturating irreversible inhibitor. (a) Plot of the natural logarithm of fractional remaining activity 
vs time to determine the rate constant for enzyme inactivation at each inhibitor concentration. (b) Plot of inactivation 
rate constants vs inhibitor concentration to determine the maximum rate of inactivation (kinactivation) and KI value (inhibitor 
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